Comparison of strength testing modalities in dysferlinopathy

Introduction/Aims Dysferlinopathy demonstrates heterogeneity in muscle weakness between patients, which can progress at different rates over time. Changing muscle strength due to disease progression or from an investigational product is associated with changing functional ability. The purpose of thi...

Full description

Saved in:
Bibliographic Details
Published inMuscle & nerve Vol. 66; no. 2; pp. 159 - 166
Main Authors Reash, Natalie F., James, Meredith K., Alfano, Lindsay N., Mayhew, Anna G., Jacobs, Marni, Iammarino, Megan A., Holsten, Scott, Sakamoto, Chikako, Tateishi, Takayuki, Yajima, Hiroyuki, Duong, Tina, Wolf, Brittney, Gee, Richard, Bharucha‐Goebel, Diana X., Bravver, Elena, Mori‐Yoshimura, Madoka, Bushby, Kate, Rufibach, Laura E., Straub, Volker, Lowes, Linda P.
Format Journal Article
LanguageEnglish
Published Hoboken, USA John Wiley & Sons, Inc 01.08.2022
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Introduction/Aims Dysferlinopathy demonstrates heterogeneity in muscle weakness between patients, which can progress at different rates over time. Changing muscle strength due to disease progression or from an investigational product is associated with changing functional ability. The purpose of this study was to compare three methods of strength testing used in the Clinical Outcome Study (COS) for dysferlinopathy to understand which method and which muscle groups were most sensitive to change over time. Methods Patients were evaluated at each study visit using functional scales, manual muscle testing, and handheld dynamometry (HHD) at all 15 sites. A fixed‐frame system (Fixed) was used at a subset of seven sites. Screening and baseline visits were evaluated for reliability. Data over a 1‐year period were analyzed to determine sensitivity to change among strength modalities and individual muscle groups. Results HHD and Fixed captured significant change across 1 year in summed muscle strength score of four muscle groups (P < .01). Strength summed scores were significantly correlated with functional scales (rho = 0.68‐0.92, P < .001). Individual muscle groups, however, showed high levels of variability between visits. Discussion Although both HHD and Fixed demonstrate change over 12 months, HHD is a less expensive option that provides data on a continuous scale and may be easier to implement. Due to variability in strength measures, researchers should carefully consider use of strength testing as an outcome and may wish to select functional measures with less variability as clinical trial endpoints.
AbstractList Abstract Introduction/Aims Dysferlinopathy demonstrates heterogeneity in muscle weakness between patients, which can progress at different rates over time. Changing muscle strength due to disease progression or from an investigational product is associated with changing functional ability. The purpose of this study was to compare three methods of strength testing used in the Clinical Outcome Study (COS) for dysferlinopathy to understand which method and which muscle groups were most sensitive to change over time. Methods Patients were evaluated at each study visit using functional scales, manual muscle testing, and handheld dynamometry (HHD) at all 15 sites. A fixed‐frame system (Fixed) was used at a subset of seven sites. Screening and baseline visits were evaluated for reliability. Data over a 1‐year period were analyzed to determine sensitivity to change among strength modalities and individual muscle groups. Results HHD and Fixed captured significant change across 1 year in summed muscle strength score of four muscle groups ( P  < .01). Strength summed scores were significantly correlated with functional scales (rho = 0.68‐0.92, P  < .001). Individual muscle groups, however, showed high levels of variability between visits. Discussion Although both HHD and Fixed demonstrate change over 12 months, HHD is a less expensive option that provides data on a continuous scale and may be easier to implement. Due to variability in strength measures, researchers should carefully consider use of strength testing as an outcome and may wish to select functional measures with less variability as clinical trial endpoints.
Introduction/AimsDysferlinopathy demonstrates heterogeneity in muscle weakness between patients, which can progress at different rates over time. Changing muscle strength due to disease progression or from an investigational product is associated with changing functional ability. The purpose of this study was to compare three methods of strength testing used in the Clinical Outcome Study (COS) for dysferlinopathy to understand which method and which muscle groups were most sensitive to change over time.MethodsPatients were evaluated at each study visit using functional scales, manual muscle testing, and handheld dynamometry (HHD) at all 15 sites. A fixed‐frame system (Fixed) was used at a subset of seven sites. Screening and baseline visits were evaluated for reliability. Data over a 1‐year period were analyzed to determine sensitivity to change among strength modalities and individual muscle groups.ResultsHHD and Fixed captured significant change across 1 year in summed muscle strength score of four muscle groups (P < .01). Strength summed scores were significantly correlated with functional scales (rho = 0.68‐0.92, P < .001). Individual muscle groups, however, showed high levels of variability between visits.DiscussionAlthough both HHD and Fixed demonstrate change over 12 months, HHD is a less expensive option that provides data on a continuous scale and may be easier to implement. Due to variability in strength measures, researchers should carefully consider use of strength testing as an outcome and may wish to select functional measures with less variability as clinical trial endpoints.
Dysferlinopathy demonstrates heterogeneity in muscle weakness between patients, which can progress at different rates over time. Changing muscle strength due to disease progression or from an investigational product is associated with changing functional ability. The purpose of this study was to compare three methods of strength testing used in the Clinical Outcome Study (COS) for dysferlinopathy to understand which method and which muscle groups were most sensitive to change over time. Patients were evaluated at each study visit using functional scales, manual muscle testing, and handheld dynamometry (HHD) at all 15 sites. A fixed-frame system (Fixed) was used at a subset of seven sites. Screening and baseline visits were evaluated for reliability. Data over a 1-year period were analyzed to determine sensitivity to change among strength modalities and individual muscle groups. HHD and Fixed captured significant change across 1 year in summed muscle strength score of four muscle groups (P < .01). Strength summed scores were significantly correlated with functional scales (rho = 0.68-0.92, P < .001). Individual muscle groups, however, showed high levels of variability between visits. Although both HHD and Fixed demonstrate change over 12 months, HHD is a less expensive option that provides data on a continuous scale and may be easier to implement. Due to variability in strength measures, researchers should carefully consider use of strength testing as an outcome and may wish to select functional measures with less variability as clinical trial endpoints.
Introduction/Aims Dysferlinopathy demonstrates heterogeneity in muscle weakness between patients, which can progress at different rates over time. Changing muscle strength due to disease progression or from an investigational product is associated with changing functional ability. The purpose of this study was to compare three methods of strength testing used in the Clinical Outcome Study (COS) for dysferlinopathy to understand which method and which muscle groups were most sensitive to change over time. Methods Patients were evaluated at each study visit using functional scales, manual muscle testing, and handheld dynamometry (HHD) at all 15 sites. A fixed‐frame system (Fixed) was used at a subset of seven sites. Screening and baseline visits were evaluated for reliability. Data over a 1‐year period were analyzed to determine sensitivity to change among strength modalities and individual muscle groups. Results HHD and Fixed captured significant change across 1 year in summed muscle strength score of four muscle groups (P < .01). Strength summed scores were significantly correlated with functional scales (rho = 0.68‐0.92, P < .001). Individual muscle groups, however, showed high levels of variability between visits. Discussion Although both HHD and Fixed demonstrate change over 12 months, HHD is a less expensive option that provides data on a continuous scale and may be easier to implement. Due to variability in strength measures, researchers should carefully consider use of strength testing as an outcome and may wish to select functional measures with less variability as clinical trial endpoints.
Author Yajima, Hiroyuki
Bushby, Kate
Lowes, Linda P.
Rufibach, Laura E.
Holsten, Scott
Wolf, Brittney
Duong, Tina
Gee, Richard
Straub, Volker
Alfano, Lindsay N.
Mori‐Yoshimura, Madoka
Bravver, Elena
Mayhew, Anna G.
James, Meredith K.
Sakamoto, Chikako
Tateishi, Takayuki
Jacobs, Marni
Iammarino, Megan A.
Bharucha‐Goebel, Diana X.
Reash, Natalie F.
Author_xml – sequence: 1
  givenname: Natalie F.
  orcidid: 0000-0002-0573-9504
  surname: Reash
  fullname: Reash, Natalie F.
  email: natalie.reash@nationwidechildrens.org
  organization: The Abigail Wexner Research Institute at Nationwide Children's Hospital
– sequence: 2
  givenname: Meredith K.
  orcidid: 0000-0001-8078-7744
  surname: James
  fullname: James, Meredith K.
  organization: Newcastle University and Newcastle Hospitals NHS Foundation Trust
– sequence: 3
  givenname: Lindsay N.
  surname: Alfano
  fullname: Alfano, Lindsay N.
  organization: The Abigail Wexner Research Institute at Nationwide Children's Hospital
– sequence: 4
  givenname: Anna G.
  surname: Mayhew
  fullname: Mayhew, Anna G.
  organization: Newcastle University and Newcastle Hospitals NHS Foundation Trust
– sequence: 5
  givenname: Marni
  orcidid: 0000-0001-6649-6692
  surname: Jacobs
  fullname: Jacobs, Marni
  organization: George Washington University
– sequence: 6
  givenname: Megan A.
  surname: Iammarino
  fullname: Iammarino, Megan A.
  organization: The Abigail Wexner Research Institute at Nationwide Children's Hospital
– sequence: 7
  givenname: Scott
  surname: Holsten
  fullname: Holsten, Scott
  organization: Carolinas HealthCare System
– sequence: 8
  givenname: Chikako
  surname: Sakamoto
  fullname: Sakamoto, Chikako
  organization: National Center of Neurology and Psychiatry
– sequence: 9
  givenname: Takayuki
  surname: Tateishi
  fullname: Tateishi, Takayuki
  organization: National Center of Neurology and Psychiatry
– sequence: 10
  givenname: Hiroyuki
  surname: Yajima
  fullname: Yajima, Hiroyuki
  organization: National Center of Neurology and Psychiatry
– sequence: 11
  givenname: Tina
  surname: Duong
  fullname: Duong, Tina
  organization: Stanford University School of Medicine
– sequence: 12
  givenname: Brittney
  surname: Wolf
  fullname: Wolf, Brittney
  organization: Children's National Health System
– sequence: 13
  givenname: Richard
  surname: Gee
  fullname: Gee, Richard
  organization: Lucile Salter Packard Children's Hospital at Stanford, Neurology
– sequence: 14
  givenname: Diana X.
  surname: Bharucha‐Goebel
  fullname: Bharucha‐Goebel, Diana X.
  organization: National Institute of Neurological Disorders and Stroke, National Institutes of Health
– sequence: 15
  givenname: Elena
  surname: Bravver
  fullname: Bravver, Elena
  organization: Carolinas HealthCare System
– sequence: 16
  givenname: Madoka
  surname: Mori‐Yoshimura
  fullname: Mori‐Yoshimura, Madoka
  organization: National Center of Neurology and Psychiatry
– sequence: 17
  givenname: Kate
  surname: Bushby
  fullname: Bushby, Kate
  organization: Newcastle University and Newcastle Hospitals NHS Foundation Trust
– sequence: 18
  givenname: Laura E.
  surname: Rufibach
  fullname: Rufibach, Laura E.
  organization: The Jain Foundation
– sequence: 19
  givenname: Volker
  orcidid: 0000-0001-9046-3540
  surname: Straub
  fullname: Straub, Volker
  organization: Newcastle University and Newcastle Hospitals NHS Foundation Trust
– sequence: 20
  givenname: Linda P.
  surname: Lowes
  fullname: Lowes, Linda P.
  organization: The Abigail Wexner Research Institute at Nationwide Children's Hospital
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35506767$$D View this record in MEDLINE/PubMed
BookMark eNp10M1LwzAYx_EgE_eiB_8BKXjRQ92TpkkW8CLDN5h40IG3kjXJltEmM2mR_fd2bHoQPD2XD19-PEPUc95phM4x3GCAbFy38SbjlMMRGmAQPM2pmPTQAHA-SRkRH300jHENAHjC-AnqE0qBccYH6Hbq640MNnqXeJPEJmi3bFZJo2Nj3TKpvZKVbayOiXWJ2kajQ2Wd38hmtT1Fx0ZWUZ8d7gjNH-7fp0_p7PXxeXo3S0tCCaRZjnEmpTaKYWqyhS6ZMkpmoCjPSwYGc16WRHGKJ8JobXLIRam6iQsBICUZoat9dxP8Z9stK2obS11V0mnfxiJjVDAgmJKOXv6ha98G163rlMCC5DiDTl3vVRl8jEGbYhNsLcO2wFDsXlrUu-zupZ29OBTbRa3Vr_z5YQfGe_BlK739v1S8zN_2yW_CgYIC
CitedBy_id crossref_primary_10_1186_s12883_024_03588_1
crossref_primary_10_19163_2307_9266_2022_10_5_483_496
Cites_doi 10.2519/jospt.1991.13.4.191
10.1212/WNL.0000000000007265
10.1515/med-2017-0052
10.1213/ANE.0000000000002864
10.1016/S0895-4356(99)00206-1
10.1002/mus.25045
10.1002/mus.21544
10.1002/ana.26044
10.1007/BF00313939
10.1161/STROKEAHA.108.530584
10.1212/WNL.44.3_Part_1.442
10.1001/jamaneurol.2020.1484
10.1038/1689
10.1016/j.omtn.2018.08.013
10.1093/brain/109.1.31
10.1002/mus.20654
10.1212/NXG.0000000000000089
10.1016/j.nmd.2021.01.009
10.1212/WNL.0b013e3181ea1564
10.1001/jamaneurol.2020.1264
10.1186/1750-1172-8-26
10.1371/journal.pone.0219854
10.1089/hum.2017.062
10.1038/1682
10.1136/jnnp-2017-317488
10.1089/hum.2019.006
10.1055/s-0034-1396008
10.1002/acn3.51235
10.1212/WNL.0000000000006858
ContentType Journal Article
Copyright 2022 Wiley Periodicals LLC.
Copyright_xml – notice: 2022 Wiley Periodicals LLC.
CorporateAuthor Jain COS Consortium
for the Jain COS Consortium
CorporateAuthor_xml – name: Jain COS Consortium
– name: for the Jain COS Consortium
DBID NPM
AAYXX
CITATION
7T5
7TK
7TM
7TS
7U7
7U9
C1K
H94
K9.
NAPCQ
7X8
DOI 10.1002/mus.27570
DatabaseName PubMed
CrossRef
Immunology Abstracts
Neurosciences Abstracts
Nucleic Acids Abstracts
Physical Education Index
Toxicology Abstracts
Virology and AIDS Abstracts
Environmental Sciences and Pollution Management
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
MEDLINE - Academic
DatabaseTitle PubMed
CrossRef
Nursing & Allied Health Premium
Virology and AIDS Abstracts
Toxicology Abstracts
Nucleic Acids Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Immunology Abstracts
Neurosciences Abstracts
Physical Education Index
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitleList CrossRef
Nursing & Allied Health Premium
MEDLINE - Academic
PubMed

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1097-4598
EndPage 166
ExternalDocumentID 10_1002_mus_27570
35506767
MUS27570
Genre article
Journal Article
GrantInformation_xml – fundername: Jain Foundation
– fundername: Medical Research Council
  funderid: MR/K000608/1
– fundername: NIHR Newcastle Biomedical Research Centre
– fundername: Medical Research Council
  grantid: MR/K000608/1
GroupedDBID ---
-~X
.3N
.55
.GA
.GJ
.Y3
05W
0R~
10A
123
1CY
1L6
1OB
1OC
1ZS
31~
33P
3O-
3SF
3WU
4.4
4ZD
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5VS
66C
6PF
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AANLZ
AAONW
AAQQT
AASGY
AAWTL
AAXRX
AAZKR
ABCQN
ABCUV
ABEML
ABIJN
ABJNI
ABLJU
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACSCC
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFNX
AFFPM
AFGKR
AFPWT
AFRAH
AFZJQ
AHBTC
AHMBA
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR1
DR2
DRFUL
DRMAN
DRSTM
EBD
EBS
EJD
EMOBN
F00
F01
F04
F5P
FEDTE
FUBAC
FYBCS
G-S
G.N
GNP
GODZA
H.X
HBH
HF~
HGLYW
HHY
HHZ
HVGLF
HZ~
IX1
J0M
JPC
KBYEO
KQQ
LATKE
LAW
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
M6M
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
NNB
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
QRW
R.K
RIWAO
RJQFR
ROL
RWD
RWI
RX1
RYL
SAMSI
SUPJJ
SV3
TEORI
TUS
TWZ
UB1
V2E
W8V
W99
WBKPD
WH7
WHWMO
WIB
WIH
WIJ
WIK
WJL
WOHZO
WQJ
WRC
WUP
WVDHM
WXI
WXSBR
X7M
XG1
XPP
XV2
YCJ
ZGI
ZXP
ZZTAW
~IA
~WT
NPM
AAYXX
CITATION
7T5
7TK
7TM
7TS
7U7
7U9
C1K
H94
K9.
NAPCQ
7X8
ID FETCH-LOGICAL-c3530-24112aaefd615f2bec6dfda20d574c60f177cc3d75189feef4049cd506b900aa3
IEDL.DBID DR2
ISSN 0148-639X
IngestDate Fri Aug 16 01:27:42 EDT 2024
Thu Oct 10 22:18:26 EDT 2024
Fri Aug 23 04:04:52 EDT 2024
Sat Sep 28 08:19:31 EDT 2024
Sat Aug 24 01:02:56 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords outcome measure
handheld dynamometry
strength
limb girdle muscular dystrophy
dysferlinopathy
Language English
License 2022 Wiley Periodicals LLC.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3530-24112aaefd615f2bec6dfda20d574c60f177cc3d75189feef4049cd506b900aa3
Notes Funding information
Jain Foundation; Medical Research Council, Grant/Award Number: MR/K000608/1; NIHR Newcastle Biomedical Research Centre
Elena Bravver deceased.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0001-9046-3540
0000-0001-6649-6692
0000-0002-0573-9504
0000-0001-8078-7744
PMID 35506767
PQID 2691934120
PQPubID 1016420
PageCount 8
ParticipantIDs proquest_miscellaneous_2659603153
proquest_journals_2691934120
crossref_primary_10_1002_mus_27570
pubmed_primary_35506767
wiley_primary_10_1002_mus_27570_MUS27570
PublicationCentury 2000
PublicationDate August 2022
PublicationDateYYYYMMDD 2022-08-01
PublicationDate_xml – month: 08
  year: 2022
  text: August 2022
PublicationDecade 2020
PublicationPlace Hoboken, USA
PublicationPlace_xml – name: Hoboken, USA
– name: United States
– name: Rochester
PublicationTitle Muscle & nerve
PublicationTitleAlternate Muscle Nerve
PublicationYear 2022
Publisher John Wiley & Sons, Inc
Wiley Subscription Services, Inc
Publisher_xml – name: John Wiley & Sons, Inc
– name: Wiley Subscription Services, Inc
References 2018; 29
2010; 75
2019; 92
2009; 40
2021; 89
2019; 30
1991; 13
2018; 126
2019; 14
2016; 54
1976
1994; 44
2020; 77
2018; 89
2013; 8
1998; 20
2003; 30
2007; 35
2010; 41
2020; 7
1986; 109
1984; 231
2021; 31
2016; 2
2000; 53
2017; 12
2014; 34
2018; 13
e_1_2_12_4_1
e_1_2_12_3_1
e_1_2_12_6_1
e_1_2_12_5_1
e_1_2_12_18_1
e_1_2_12_2_1
e_1_2_12_17_1
e_1_2_12_16_1
e_1_2_12_20_1
e_1_2_12_21_1
e_1_2_12_22_1
e_1_2_12_23_1
e_1_2_12_24_1
e_1_2_12_25_1
e_1_2_12_26_1
e_1_2_12_27_1
Rider LG (e_1_2_12_28_1) 2003; 30
e_1_2_12_29_1
e_1_2_12_30_1
e_1_2_12_31_1
e_1_2_12_32_1
e_1_2_12_15_1
e_1_2_12_14_1
e_1_2_12_13_1
e_1_2_12_12_1
e_1_2_12_8_1
e_1_2_12_11_1
Medical Research Council (e_1_2_12_19_1) 1976
e_1_2_12_7_1
e_1_2_12_10_1
e_1_2_12_9_1
References_xml – volume: 54
  start-page: 203
  year: 2016
  end-page: 210
  article-title: Broadening the imaging phenotype of dysferlinopathy at different disease stages
  publication-title: Muscle Nerve
– volume: 109
  start-page: 31
  year: 1986
  end-page: 54
  article-title: Autosomal recessive distal muscular dystrophy as a new type of progressive muscular dystrophy. Seventeen cases in eight families including an autopsied case
  publication-title: Brain
– volume: 14
  year: 2019
  article-title: Intraclass correlation‐‐‐a discussion and demonstration of basic features
  publication-title: PLoS One
– volume: 8
  start-page: 26
  year: 2013
  article-title: Treatment of dysferlinopathy with deflazacort: a double‐blind, placebo‐controlled clinical trial
  publication-title: Orphanet J Rare Dis
– volume: 2
  year: 2016
  article-title: The clinical outcome study for dysferlinopathy: an international multicenter study
  publication-title: Neurol Genet
– volume: 20
  start-page: 37
  year: 1998
  end-page: 42
  article-title: A gene related to spermatogenesis factor fer‐1 is mutated in limb‐girdle muscular dystrophy type 2B
  publication-title: Nat Genet
– volume: 30
  start-page: 794
  year: 2019
  end-page: 801
  article-title: Gene delivery for limb‐girdle muscular dystrophy type 2D by isolated limb infusion
  publication-title: Hum Gene Ther
– volume: 53
  start-page: 459
  year: 2000
  end-page: 468
  article-title: Methods for assessing responsiveness: a critical review and recommendations
  publication-title: J Clin Epidemiol
– volume: 29
  start-page: 749
  year: 2018
  end-page: 762
  article-title: Systemic delivery of dysferlin overlap vectors provides long‐term gene expression and functional improvement for dysferlinopathy
  publication-title: Hum Gene Ther
– volume: 13
  start-page: 198
  year: 2018
  end-page: 207
  article-title: Exon skipping in a Dysf‐missense mutant mouse model
  publication-title: Mol Ther Nucleic Acids
– volume: 126
  start-page: 1763
  year: 2018
  end-page: 1768
  article-title: Correlation coefficients: appropriate use and interpretation
  publication-title: Anesth Analg
– volume: 7
  start-page: 2393
  year: 2020
  end-page: 2408
  article-title: Viltolarsen in Japanese Duchenne muscular dystrophy patients: a phase 1/2 study
  publication-title: Ann Clin Transl Neurol
– volume: 44
  start-page: 442
  year: 1994
  end-page: 446
  article-title: Facioscapulohumeral muscular dystrophy (FSHD): design of natural history study and results of baseline testing
  publication-title: Neurology
– volume: 40
  start-page: 1386
  year: 2009
  end-page: 1391
  article-title: Responsiveness and validity of three outcome measures of motor function after stroke rehabilitation
  publication-title: Stroke
– volume: 92
  start-page: e461
  year: 2019
  end-page: e474
  article-title: Assessment of disease progression in dysferlinopathy: a 1‐year cohort study
  publication-title: Neurology
– volume: 35
  start-page: 36
  year: 2007
  end-page: 42
  article-title: Reliable surrogate outcome measures in multicenter clinical trials of Duchenne muscular dystrophy
  publication-title: Muscle Nerve
– volume: 20
  start-page: 31
  year: 1998
  end-page: 36
  article-title: Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy
  publication-title: Nat Genet
– volume: 75
  start-page: 316
  year: 2010
  end-page: 323
  article-title: Redefining dysferlinopathy phenotypes based on clinical findings and muscle imaging studies
  publication-title: Neurology
– volume: 92
  start-page: e1773
  year: 2019
  end-page: e1785
  article-title: Community exercise is feasible for neuromuscular diseases and can improve aerobic capacity
  publication-title: Neurology
– volume: 30
  start-page: 603
  year: 2003
  end-page: 617
  article-title: Defining clinical improvement in adult and juvenile myositis
  publication-title: J Rheumatol
– volume: 77
  start-page: 982
  year: 2020
  end-page: 991
  article-title: Safety, tolerability, and efficacy of Viltolarsen in boys with Duchenne muscular dystrophy amenable to exon 53 skipping: a phase 2 randomized clinical trial
  publication-title: JAMA Neurol
– volume: 89
  start-page: 1071
  year: 2018
  end-page: 1081
  article-title: Muscle MRI in patients with dysferlinopathy: pattern recognition and implications for clinical trials
  publication-title: J Neurol Neurosurg Psychiatry
– volume: 231
  start-page: 200
  year: 1984
  end-page: 203
  article-title: Measuring muscle strength
  publication-title: J Neurol
– volume: 12
  start-page: 359
  year: 2017
  end-page: 375
  article-title: Absolute reliability and concurrent validity of hand held dynamometry and isokinetic dynamometry in the hip, knee and ankle joint: systematic review and meta‐analysis
  publication-title: Open Med (Wars)
– volume: 41
  start-page: 500
  year: 2010
  end-page: 510
  article-title: The 6‐minute walk test as a new outcome measure in Duchenne muscular dystrophy
  publication-title: Muscle Nerve
– volume: 89
  start-page: 967
  year: 2021
  end-page: 978
  article-title: Assessing Dysferlinopathy patients over three years with a new motor scale
  publication-title: Ann Neurol
– volume: 13
  start-page: 191
  year: 1991
  end-page: 198
  article-title: Hand‐held dynamometer measurements: tester strength makes a difference
  publication-title: J Orthop Sports Phys Ther
– volume: 34
  start-page: 542
  year: 2014
  end-page: 556
  article-title: Exercise in neuromuscular disease
  publication-title: Semin Neurol
– year: 1976
– volume: 31
  start-page: 265
  year: 2021
  end-page: 280
  article-title: Miyoshi myopathy and limb girdle muscular dystrophy R2 are the same disease
  publication-title: Neuromuscul Disord.
– volume: 77
  start-page: 1122
  year: 2020
  end-page: 1131
  article-title: Assessment of systemic delivery of rAAVrh74.MHCK7.Micro‐dystrophin in children with Duchenne muscular dystrophy: a nonrandomized controlled trial
  publication-title: JAMA Neurol
– ident: e_1_2_12_29_1
  doi: 10.2519/jospt.1991.13.4.191
– volume-title: Aids to the Investigation of Peripheral Nerve Injuries
  year: 1976
  ident: e_1_2_12_19_1
  contributor:
    fullname: Medical Research Council
– ident: e_1_2_12_32_1
  doi: 10.1212/WNL.0000000000007265
– ident: e_1_2_12_27_1
  doi: 10.1515/med-2017-0052
– ident: e_1_2_12_24_1
  doi: 10.1213/ANE.0000000000002864
– ident: e_1_2_12_25_1
  doi: 10.1016/S0895-4356(99)00206-1
– ident: e_1_2_12_6_1
  doi: 10.1002/mus.25045
– ident: e_1_2_12_23_1
  doi: 10.1002/mus.21544
– ident: e_1_2_12_17_1
  doi: 10.1002/ana.26044
– ident: e_1_2_12_20_1
  doi: 10.1007/BF00313939
– ident: e_1_2_12_26_1
  doi: 10.1161/STROKEAHA.108.530584
– ident: e_1_2_12_22_1
  doi: 10.1212/WNL.44.3_Part_1.442
– ident: e_1_2_12_13_1
  doi: 10.1001/jamaneurol.2020.1484
– volume: 30
  start-page: 603
  year: 2003
  ident: e_1_2_12_28_1
  article-title: Defining clinical improvement in adult and juvenile myositis
  publication-title: J Rheumatol
  contributor:
    fullname: Rider LG
– ident: e_1_2_12_2_1
  doi: 10.1038/1689
– ident: e_1_2_12_15_1
  doi: 10.1016/j.omtn.2018.08.013
– ident: e_1_2_12_4_1
  doi: 10.1093/brain/109.1.31
– ident: e_1_2_12_21_1
  doi: 10.1002/mus.20654
– ident: e_1_2_12_5_1
  doi: 10.1212/NXG.0000000000000089
– ident: e_1_2_12_9_1
  doi: 10.1016/j.nmd.2021.01.009
– ident: e_1_2_12_8_1
  doi: 10.1212/WNL.0b013e3181ea1564
– ident: e_1_2_12_10_1
  doi: 10.1001/jamaneurol.2020.1264
– ident: e_1_2_12_14_1
  doi: 10.1186/1750-1172-8-26
– ident: e_1_2_12_30_1
  doi: 10.1371/journal.pone.0219854
– ident: e_1_2_12_16_1
  doi: 10.1089/hum.2017.062
– ident: e_1_2_12_3_1
  doi: 10.1038/1682
– ident: e_1_2_12_7_1
  doi: 10.1136/jnnp-2017-317488
– ident: e_1_2_12_12_1
  doi: 10.1089/hum.2019.006
– ident: e_1_2_12_31_1
  doi: 10.1055/s-0034-1396008
– ident: e_1_2_12_11_1
  doi: 10.1002/acn3.51235
– ident: e_1_2_12_18_1
  doi: 10.1212/WNL.0000000000006858
SSID ssj0001867
Score 2.443585
Snippet Introduction/Aims Dysferlinopathy demonstrates heterogeneity in muscle weakness between patients, which can progress at different rates over time. Changing...
Dysferlinopathy demonstrates heterogeneity in muscle weakness between patients, which can progress at different rates over time. Changing muscle strength due...
Abstract Introduction/Aims Dysferlinopathy demonstrates heterogeneity in muscle weakness between patients, which can progress at different rates over time....
Introduction/AimsDysferlinopathy demonstrates heterogeneity in muscle weakness between patients, which can progress at different rates over time. Changing...
INTRODUCTION/AIMSDysferlinopathy demonstrates heterogeneity in muscle weakness between patients, which can progress at different rates over time. Changing...
SourceID proquest
crossref
pubmed
wiley
SourceType Aggregation Database
Index Database
Publisher
StartPage 159
SubjectTerms dysferlinopathy
Evaluation
handheld dynamometry
Heterogeneity
limb girdle muscular dystrophy
Muscle strength
outcome measure
Patients
Reliability analysis
Sensitivity analysis
strength
Strength testing
Variability
Title Comparison of strength testing modalities in dysferlinopathy
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fmus.27570
https://www.ncbi.nlm.nih.gov/pubmed/35506767
https://www.proquest.com/docview/2691934120
https://search.proquest.com/docview/2659603153
Volume 66
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8QwEB7Eg3jx_VhdpYoHL91t06Rp0IuoyyLoQV3Yg1DSplERW3G7h_XXO0m3XVQE8daSpmkzmc43zcw3AEeKSkGThLpcSeFS5kduRPAU0aufcWGSL22U703YH9CrIRvOwUmdC1PxQzQ_3Ixm2O-1UXCZjLoz0tDX8ahDOOPGX_cDbsK5Lm5n1FGGqK0KX4xctMLDmlXII92m51db9ANgfsWr1uD0luGhftQqzuSlMy6TTvrxjcXxn--yAktTIOqcVStnFeayfA0Wrqdb7etwet5UKHQK7ZickvyxfHJKQ8uRPzqvhTIQHh1t5zl31GSkLXFWYUocTzZg0Lu8P--701ILbhqwwHPRjvtEykwrRDiaoGBDpZUknmKcpqGnfc7TNFBmk0boLNMUPYtUMS9MhOdJGWzCfF7k2TY4OtKJIoJKP0qolqGMJN6I8FQQhfiCteCwnvT4rWLUiCvuZBLjPMR2HlrQrsURT5UKW0KBcJP6BJsPmmZUB7PHIfOsML1DJkzhbBa0YKsSYzMKQivP8NO14NgK4_fh4-vBnT3Y-fulu7BITGqEDQ5sw3z5Ps72ELCUyb5dmZ_jO-ZE
link.rule.ids 315,783,787,1378,27938,27939,46308,46732
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT4QwEJ4YTdSL78fqqmg8eGGF0gJNvJhVs-quB3WTvRhSKFVjBKPsQX-907JgVmNivEFKael0mK_tzDcA-5IKTuOY2oEU3KbMDe2Q4C2iVzcNuA6-NF6-V36nTy8GbDABR1UsTMkPUW-4ac0w_2ut4HpD-vCLNfR5-NYiAQtwwT6F6u7p_AUn11_kUZqqrXRgDG20w4OKV8ghh3XVcWv0A2KOI1Zjcs7m4a7qbOlp8tQaFnEr-fjG4_jfr1mAuREWtY7LybMIE2m2BNO90Wn7Mhy16ySFVq4sHVaS3RcPVqGZObJ76zmXGsXjWtt6zCz5_qYMd1ausxy_r0D_7PS23bFH2RbsxGOeY6Mpd4kQqZIIchRB2fpSSUEcyQKa-I5ygyBJPKnPabhKU0VxcZFI5vgxdxwhvFWYzPIsXQdLhSqWhFPhhjFVwhehwBeRIOFEIsRgDdirRj16KUk1opI-mUQ4DpEZhwY0K3lEI73CEp8j4qQuweLduhg1Qh9ziCzNdW2fcZ07m3kNWCvlWLeC6MrRFHUNODDS-L35qNe_MRcbf390B2Y6t71u1D2_utyEWaIjJYyvYBMmi9dhuoX4pYi3zTT9BERE6l4
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT4QwEJ4YTYwX34_1icaDF9ZSWqDRi1E3vmPUTfZgQgqlaoxglD3or3daFowaE-MNUkqh02G-oTPfAGwqJgVLEuaGSgqXcS9yI4qniF69LBQm-dJG-V4ER1120uO9Idipc2Eqfojmh5vRDPu9Ngr-rPT2J2noU_-1TUMeor8-wgKfmHiug6tP7ijD1FbFL0YumuFeTStE6HbT9asx-oEwvwJWa3E6E3BbP2sVaPLY7pdJO33_RuP4z5eZhPEBEnX2qqUzBUNZPg2j54O99hnY3W9KFDqFdkxSSX5X3jul4eXI75ynQhkMj56285A76u1VW-aswtQ4fpuFbufwZv_IHdRacFOf-8RFQ-5RKTOtEOJoipINlFaSEsVDlgZEe2GYpr4yuzRCZ5lm6FqkipMgEYRI6c_BcF7k2QI4OtKJooJJL0qYloGMJN6IhqmgCgEGb8FGPenxc0WpEVfkyTTGeYjtPLRguRZHPNAqbAkE4k3mUWxeb5pRH8wmh8yzwvQOuDCVs7nfgvlKjM0oiK2IIahrwZYVxu_Dx-fda3uw-PdL12D08qATnx1fnC7BGDVpEjZQcBmGy5d-toLgpUxW7SL9AJ4V6Q0
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comparison+of+strength+testing+modalities+in+dysferlinopathy&rft.jtitle=Muscle+%26+nerve&rft.au=Reash%2C+Natalie+F&rft.au=James%2C+Meredith+K&rft.au=Alfano%2C+Lindsay+N&rft.au=Mayhew%2C+Anna+G&rft.date=2022-08-01&rft.pub=Wiley+Subscription+Services%2C+Inc&rft.issn=0148-639X&rft.eissn=1097-4598&rft.volume=66&rft.issue=2&rft.spage=159&rft.epage=166&rft_id=info:doi/10.1002%2Fmus.27570&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0148-639X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0148-639X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0148-639X&client=summon